Jinyao Pharmaceutical: Subsidiary drugs pass generic drug consistency evaluation.

Tianjin Pharmaceutical Industry announced that its subsidiary Tianjin Yaopingheping has received the "Drug Supplementary Application Approval Letter" issued by the National Medical Products Administration for the compound potassium hydrogen phosphate injection, approving the product's consistency evaluation in terms of generic drug quality and efficacy. The compound potassium hydrogen phosphate injection, used as a phosphate supplement, is mainly used to correct hypophosphatemia in adult and pediatric patients, as well as in parenteral nutrition. Tianjin Yaopingheping has accumulated approximately 9.21 million yuan in research and development investment in this project. The domestic sales of compound potassium hydrogen phosphate injection in 2023 and 2024 are expected to be 343 million yuan and 413 million yuan, respectively. The consistency evaluation is beneficial for enhancing the market competitiveness of this drug and will have a positive impact on the company's performance.